Patients in the UK and Singapore could gain faster access to cutting-edge healthcare innovations under a new partnership bringing two globally respected regulators together with one of the world’s leading biotech creators.
Similar Posts
MHRA approves tisotumab vedotin for the treatment of cervical cancer
As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used
Find product information about medicines
How to get information including patient information leaflets (PILs), details on how the medicine can be used (SmPCs) and scientific reports (PARs).
Guidance: Digital mental health technology: qualification and classification
Helping manufacturers define the characteristics of their devices and determine the appropriate regulatory qualification and classification.
MHRA statement on Pathways clinical trial
As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants.
Supplying authorised medicines to Northern Ireland
What you need to do to supply authorised medicines from Great Britain to Northern Ireland.
Professor Bola Owolabi CBE: Creating the Climate for Health Equity
Exploring the MHRA’s transformational impact on access, experience, and outcomes.